Teva Pharmaceutical Industries Limited (TEVA) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in Tel Aviv, Israel. Der aktuelle CEO ist Richard D. Francis.
TEVA hat IPO-Datum 1982-02-16, 37,000 Vollzeitbeschäftigte, gelistet an der NYSE, eine Marktkapitalisierung von $36.99B.
Teva Pharmaceutical Industries Limited is a global pharmaceutical company headquartered in Tel Aviv, Israel, that develops, manufactures, and distributes generic medicines, specialty medicines, and biopharmaceutical products across North America, Europe, and international markets. The company operates across multiple therapeutic areas including central nervous system, pain, respiratory, and oncology, offering products in diverse dosage forms such as tablets, injectables, inhalants, and transdermal patches. Its portfolio includes well-known brands such as Copaxone for multiple sclerosis, AJOVY for migraine prevention, and AUSTEDO for movement disorders, alongside respiratory treatments including ProAir and QVAR for asthma and COPD, and oncology products such as Treanda and Granix. Teva also manufactures active pharmaceutical ingredients and collaborates with partners like MedinCell to develop long-acting injectable formulations. Founded in 1901, the company has established itself as a major player in the global pharmaceutical industry.
